Across TCGA pan-cancer cohorts, KRTAP12-3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP12-3 data layer compared with 14 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher KRTAP12-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP12-3 expression acts as an unfavorable survival marker.

THYM, BRCA, and PCPG are the cancer types where KRTAP12-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.039	0.928	<.001	24	view →
BRCA	DFS	Median	All	0.140	1.000	.001	20	view →
PCPG	DFS	Median	All	0.094	0.768	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP12-3 tumor-vs-normal RNA expression · all KRTAP12-3 data types